References in periodicals archive ?
This US FDA clearance of gammaCore for the acute treatment of pain associated with migraine was principally supported by the results of the multicentre, randomized, double-blind, sham-controlled trial, PRESTO (PRospectivE Study of nVNS for the Acute Treatment Of Migraine).
In the second phase half of the veterans will be given an active gammaCore nVNS device, and half will be given a sham (inactive) device.
ElectroCore's nVNS therapy is delivered by placing the Gammacore device against the neck over the vagus nerve where the carotid pulse is located.
electroCore's presentation in Boston represented a subset of the data it previously presented on at the INS (International Neuromodulation Society) 11th World Congress in Berlin, which illustrated that nVNS may have meaningful clinical benefits, both in offering relief from acute cluster headaches as well as reducing the frequency of attacks.
The paper also reported that nVNS is well tolerated, produced no serious side effects, and that the percentage of episodic patients who experienced a successful response to the first attack treated within 15 minutes was triple that of those using the sham - 34.2% versus 10.6% (p<0.01).
New results from the PREVA study, a randomized, prospective, controlled study of nVNS for the prevention of chronic cluster headache, was led by Dr.
In all scenarios modelled, nVNS was more cost-effective than the current standard practice.
The study which is in the July edition of the The Journal of Headache and Pain(2) reports that electroCore's nVNS treatment delivered by a gammaCore device was effective in reducing pain levels in more than 65 percent of the patients after two hours - the primary endpoint.
Valencia, Spain, May 23, 2015 --(PR.com)-- A poster at the International Headache Congress(1), in Valencia, reports on a study which examined patients' attitude to electroCore's non-invasive vagus nerve stimulation (nVNS) treatment for migraines.
Valencia, Spain, May 20, 2015 --(PR.com)-- * electroCore's gammaCore non-invasive vagus nerve stimulation (nVNS) therapy improves quality of life when added to standard of care (SOC)
Basking Ridge, NJ, April 30, 2015 --(PR.com)-- At the 67th American Academy of Neurology meeting in Washington, DC, last week a poster presentation showed that electroCore's non-invasive vagus nerve stimulation (nVNS) therapy does not cause any meaningful cardiovascular adverse effects in patients with asthma.
ElectroCore, which is based in New Jersey, is focused on developing non-invasive Vagus Nerve Stimulation (nVNS) self-administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and respiratory fields.
Acronyms browser ?
Full browser ?
- NVMe M.2 SSD
- NVMe over Fabrics